Oral vs. IV paracetamol for pain control in patients with femur fracture in the emergency department: a practical randomized controlled trial

Femur fracture (FF) is a common reason for admission to the Emergency Department (ED) and pain is a frequent symptom. Effective and timely pain control is essential for these patients, however, the most appropriate analgesic therapy for quick pain relief in the ED setting is not well established. This is a single-center pragmatic randomized controlled study. We have enrolled 171 consecutive patients with FF and severe pain. They were randomized 1:5 to receive treatment with paracetamol 1000 mg orally (OR) or with paracetamol 1000 mg intravenously (IV). The effect on pain relief was measured with the Visual Analogue Scale for Pain (VAS) at baseline (T0), after 1 hour (T1), 2 hours (T2), and 4 hours (T4). The primary endpoint was the reduction of pain of 1 point of the VAS at T1. This target was reached by 75% of patients treated with paracetamol IV and 44% treated with paracetamol OR (p = 0.001). The secondary endpoint was the reduction of pain of at least 2 points of the VAS at T4, the need for rescue therapy, and the number of adverse events. At T4 the efficacy of paracetamol IV and OR resulted in 89.5% and 88.9%, respectively (p = 0.914). The 17.5% of patients treated with paracetamol IV vs. the 3.7% treated with paracetamol OR required rescue therapy (p = 0.082), with prevalence among women (p = 0.057). No adverse effects were reported. The treatment with paracetamol 1000 mg IV and OR resulted effective and safe for patients with FF waiting for surgery. IV administration was faster in reducing pain in the first 2 hours compared to oral administration but the latter required less rescue therapy. Interestingly, our study highlighted gender differences in pain relief opening the way for a gender-tailored therapy.

Femur fracture; Pain; Paracetamol; Emergency department; Elderly

[1] Dizdarevic A, Farah F, Ding J, Shah S, Bryan A, Kahn M, et al. A comprehensive review of analgesia and pain modalities in hip fracture pathogenesis. Current Pain and Headache Reports. 2019; 23: 72.

[2] Elsoe R, Ceccotti AA, Larsen P. Population-based epidemiology and incidence of distal femur fractures. International Orthopaedics. 2018; 42: 191–196.

[3] Bonnin MP, Neto CC, Aitsiselmi T, Murphy CG, Bossard N, Roche S. Increased incidence of femoral fractures in small femurs and women undergoing uncemented total hip arthroplasty—why? The Bone & Joint Journal. 2015; 97-B: 741–748.

[4] Mattisson L, Bojan A, Enocson A. Epidemiology, treatment and mortality of trochanteric and subtrochanteric hip fractures: data from the Swedish fracture register. BMC Musculoskeletal Disorders. 2018; 19: 369.

[5] Lim SJ, Yeo I, Yoon PW, Yoo JJ, Rhyu KH, Han SB, et al. Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study. Osteoporosis International. 2018; 29: 2427–2435.

[6] Roder F. Proximal femur fracture in older patients—rehabilitation and clinical outcome. Age and Ageing. 2003; 32: 74–80.

[7] Larsen P, Ceccotti AA, Elsoe R. High mortality following distal femur fractures: a cohort study including three hundred and two distal femur fractures. International Orthopaedics. 2020; 44: 173–177.

[8] Rowlands M, Walt GVD, Bradley J, Mannings A, Armstrong S, Bedforth N, et al. Femoral nerve block intervention in neck of femur fracture (FINOF): a randomised controlled trial. BMJ Open. 2018; 8: e019650.

[9] Uysal Aİ, Altıparmak B, Yaşar E, Turan M, Canbek U, Yılmaz N, et al. The effects of early femoral nerve block intervention on preoperative pain management and incidence of postoperative delirium geriatric patients undergoing trochanteric femur fracture surgery: A randomized controlled trial. Ulus Travma Acil Cerrahi Derg. 2020; 26: 109–114.

[10] Gangavalli AK, Nwachuku CO. Management of distal femur fractures in adults. Orthopedic Clinics of North America. 2016; 47: 85–96.

[11] Oc Y, Varol A, Yazar EA, Ak S, Akpolat AO, Kilinc BE. Treatment strategy for elderly patients with the isolated greater trochanteric fracture. SAGE Open Medicine. 2020; 8: 205031212096413.

[12] Li L, Bennett-Brown K, Morgan C, Dattani R. Hip fractures. British Journal of Hospital Medicine. 2020; 81: 1–10.

[13] Fabi DW. Multimodal analgesia in the hip fracture patient. Journal of Orthopaedic Trauma. 2016; 30: S6–S11.

[14] Kuberan A, Makkar J, Jain K, Balasubramanian M, Bhatia N, Singh P. Pre-emptive multimodal analgesic regimen reduces post-operative epidural demand boluses in traumatic shaft of femur fracture—a randomised controlled trial. Indian Journal of Anaesthesia. 2019; 63: 895.

[15] Soffin EM, Gibbons MM, Wick EC, Kates SL, Cannesson M, Scott MJ, et al. Evidence review conducted for the agency for healthcare research and quality safety program for improving surgical care and recovery. Anesthesia & Analgesia. 2019; 128: 1107–1117.

[16] Chuang P, Shen S, Yang T, Huang T, Huang K. Non-steroidal anti-inflammatory drugs and the risk of a second hip fracture: a propensity-score matching study. BMC Musculoskeletal Disorders. 2016; 17: 201.

[17] Glinkowski W, Narloch J, Krasuski K, Śliwczyński A. The increase of osteoporotic hip fractures and associated one-year mortality in Poland: 2008–2015. Journal of Clinical Medicine. 2019; 8: 1487.

[18] Dixon J, Ashton F, Baker P, Charlton K, Bates C, Eardley W. Assessment and early management of pain in hip fractures: the impact of paracetamol. Geriatric Orthopaedic Surgery & Rehabilitation. 2018; 9: 215145931880644.

[19] Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care & Research. 2011; 63: S240–S252.

[20] Franceschi F, Marsiliani D, Alesi A, Mancini MG, Ojetti V, Candelli M, et al. A simplified way for the urgent treatment of somatic pain in patients admitted to the emergency room: the SUPER algorithm. Internal and Emergency Medicine. 2015; 10: 985–992.

[21] Di Filippo A, Magherini M, Ruggiano P, Ciardullo A, Falsini S. Postoperative analgesia in patients older than 75 years undergoing intervention for per-trochanteric hip fracture: a single centre retrospective cohort study. Aging Clinical and Experimental Research. 2015; 27: 281–285.

[22] Aprato A, Bechis M, Buzzone M, Bistolfi A, Daghino W, Massè A. No rest for elderly femur fracture patients: early surgery and early ambulation decrease mortality. Journal of Orthopaedics and Traumatology. 2020; 21: 12.

[23] Mubark I, Abouelela A, Genena A, Al Ghunimat A, Sarhan I, Ashwood N. Mortality following distal femur fractures versus proximal femur fractures in elderly population: the impact of best practice tariff. Cureus. 2020; 12: e10744.

[24] Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporosis International. 2012; 23: 2239–2256.

[25] Piscitelli P, Neglia C, Feola M, Rizzo E, Argentiero A, Ascolese M, et al. Updated incidence and costs of hip fractures in elderly Italian population. Aging Clinical and Experimental Research. 2020; 32: 2587–2593.

[26] Peeters CMM, Visser E, Van de Ree CLP, Gosens T, Den Oudsten BL, De Vries J. Quality of life after hip fracture in the elderly: a systematic literature review. Injury. 2016; 47: 1369–1382.

[27] Guzon-Illescas O, Perez Fernandez E, Crespí Villarias N, Quirós Donate FJ, Peña M, Alonso-Blas C, et al. Mortality after osteoporotic hip fracture: incidence, trends, and associated factors. Journal of Orthopaedic Surgery and Research. 2019; 14: 203.

[28] Mian P, Allegaert K, Spriet I, Tibboel D, Petrovic M. Paracetamol in older people: towards evidence-based dosing? Drugs & Aging. 2018; 35: 603–624.

[29] Gazelka HM, Leal JC, Lapid MI, Rummans TA. Opioids in older adults: indications, prescribing, complications, and alternative therapies for primary care. Mayo Clinic Proceedings. 2020; 95: 793–800.

[30] Gemmati D, Varani K, Bramanti B, Piva R, Bonaccorsi G, Trentini A, et al. “Bridging the gap” everything that could have been avoided if we had applied gender medicine, pharmacogenetics and personalized medicine in the gender-omics and sex-omics era. International Journal of Molecular Sciences. 2019; 21: 296.

[31] Di Sanzo M, Cipolloni L, Borro M, La Russa R, Santurro A, Scopetti M, et al. Clinical applications of personalized medicine: a new paradigm and challenge. Current Pharmaceutical Biotechnology. 2017; 18: 194–203.